litlas
Log inCreate account

Janet Schnee

Active 1987–2023

25
Papers
18,006
Citations
24
h-index
25
i10-index

Citations

Citations per year for Janet Schnee1989: 2 citations1991: 2 citations1992: 1 citations2000: 4 citations2001: 8 citations2002: 8 citations2003: 7 citations2004: 11 citations2005: 10 citations2006: 9 citations2007: 9 citations2008: 27 citations2009: 42 citations2010: 94 citations2011: 75 citations2012: 80 citations2013: 96 citations2014: 61 citations2015: 53 citations2016: 57 citations2017: 48 citations2018: 28 citations2019: 116 citations2020: 231 citations2021: 691 citations2022: 1,059 citations2023: 786 citations2024: 1,147 citations2025: 577 citations2026: 10 citations1990: no citations, so this year is not shown1993–1999: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 1,649 citing papers, 18.3% of this breakdownUnited Kingdom: 763 citing papers, 8.5% of this breakdownGermany: 608 citing papers, 6.7% of this breakdownCanada: 537 citing papers, 6% of this breakdownItaly: 501 citing papers, 5.6% of this breakdownChina: 406 citing papers, 4.5% of this breakdownNetherlands: 370 citing papers, 4.1% of this breakdownFrance: 320 citing papers, 3.5% of this breakdownJapan: 288 citing papers, 3.2% of this breakdownSweden: 258 citing papers, 2.9% of this breakdownAustralia: 237 citing papers, 2.6% of this breakdownSpain: 228 citing papers, 2.5% of this breakdown
0%18.3%Other 31.6%

Institutions

Fields

  • Medicine93.8%
  • Biochemistry, Genetics and Molecular Biology3.9%
  • Immunology and Microbiology0.8%
  • Economics, Econometrics and Finance0.2%
  • Neuroscience0.2%
  • Pharmacology, Toxicology and Pharmaceutics0.2%
  • Other0.9%

Topics

  • Diabetes Treatment and Management15.2%
  • Heart Failure Treatment and Management10.5%
  • Cardiovascular Function and Risk Factors9.5%
  • Atrial Fibrillation Management and Outcomes4.8%
  • Venous Thromboembolism Diagnosis and Management4.6%
  • Pancreatic function and diabetes3.9%
  • Other51.5%

Coauthors

All papers

Open in search
  1. Empagliflozin in Heart Failure with a Preserved Ejection Fraction

    Authors: Stefan D. Anker, Javed Butler, Gerasimos Filippatos, João Pedro Ferreira, Edimar Alcides Bocchi, Michael Böhm, Hans‐Peter Brunner‐La Rocca, Dong‐Ju Choi, Vijay Chopra, Eduardo Chuquiure‐Valenzuela, Nadia Giannetti, Juan Esteban Gómez‐Mesa, Stefan Janssens, James L. Januzzi, José Ramón González‐Juanatey, Béla Merkely, Stephen J. Nicholls, Sergio V. Perrone, Ileana L. Piña, Piotr Ponikowski, Michele Senni, David Sim, Jindřich Špinar, Iain Squire, Stefano Taddei, Hiroyuki Tsutsui, Subodh Verma, Dragoş Vinereanu, Jian Zhang, Peter E. Carson, Carolyn S.P. Lam, Nikolaus Marx, Cordula Zeller, Naveed Sattar, Waheed Jamal, Sven Schnaidt, Janet Schnee, Martina Brueckmann, Stuart Pocock, Faı̈ez Zannad, Milton Packer - New England Journal of Medicine 2021 cited by 4,618

  2. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure

    Authors: Milton Packer, Stefan D. Anker, Javed Butler, Gerasimos Filippatos, Stuart Pocock, Peter E. Carson, James L. Januzzi, Subodh Verma, Hiroyuki Tsutsui, Martina Brueckmann, Waheed Jamal, Karen Kimura, Janet Schnee, Cordula Zeller, Daniel Cotton, Edimar Alcides Bocchi, Michael Böhm, Dong‐Ju Choi, Vijay Chopra, Eduardo Chuquiure‐Valenzuela, Nadia Giannetti, Stefan Janssens, Jian Zhang, José Ramón González‐Juanatey, Sanjay Kaul, Hans‐Peter Brunner‐La Rocca, Béla Merkely, Stephen J. Nicholls, Sergio V. Perrone, Ileana L. Piña, Piotr Ponikowski, Naveed Sattar, Michele Senni, Marie‐France Seronde, Jindřich Špinar, Iain Squire, Stefano Taddei, Christoph Wanner, Faı̈ez Zannad - New England Journal of Medicine 2020 cited by 5,037

  3. Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial

    Authors: Milton Packer, Javed Butler, Faı̈ez Zannad, Gerasimos Filippatos, João Pedro Ferreira, Stuart Pocock, Peter E. Carson, Inder S. Anand, Wolfram Doehner, Markus Haass, Michel Komajda, Alan B. Miller, Steen Pehrson, John R. Teerlink, Sven Schnaidt, Cordula Zeller, Janet Schnee, Stefan D. Anker, for the EMPEROR-Preserved Trial Study Group - Circulation 2021 cited by 343

  4. Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function

    Authors: Faı̈ez Zannad, João Pedro Ferreira, Stuart Pocock, Cordula Zeller, Stefan D. Anker, Javed Butler, Gerasimos Filippatos, Sibylle J. Hauske, Martina Brueckmann, Egon Pfarr, Janet Schnee, Christoph Wanner, Milton Packer - Circulation 2020 cited by 278

  5. Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction

    Authors: Javed Butler, Milton Packer, Gerasimos Filippatos, João Pedro Ferreira, Cordula Zeller, Janet Schnee, Martina Brueckmann, Stuart Pocock, Faı̈ez Zannad, Stefan D. Anker - European Heart Journal 2021 cited by 253

  6. Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism

    Authors: Sam Schulman, Clive Kearon, Ajay K. Kakkar, Patrick Mismetti, Sebastian Schellong, Henry Eriksson, David Baanstra, Janet Schnee, Samuel Z. Goldhaber - New England Journal of Medicine 2009 cited by 2,571

  7. Angiotensin II, adhesion, and cardiac fibrosis

    Authors: Janet Schnee - Cardiovascular Research 2000 cited by 253

  8. Prognostic Importance of NT-proBNP and Effect of Empagliflozin in the EMPEROR-Reduced Trial

    Authors: James L. Januzzi, Faı̈ez Zannad, Stefan D. Anker, Javed Butler, Gerasimos Filippatos, Stuart Pocock, João Pedro Ferreira, Naveed Sattar, Subodh Verma, Ola Vedin, Janet Schnee, Tomoko Iwata, Dan Cotton, Milton Packer - Journal of the American College of Cardiology 2021 cited by 101

  9. Baseline Characteristics of Patients with Heart Failure with Preserved Ejection Fraction in the EMPEROR-Preserved Trial

    Authors: Stefan D. Anker, Javed Butler, Gerasimos Filippatos, Muhammad Shahzeb Khan, João Pedro Ferreira, Edimar Alcides Bocchi, Michael Böhm, Hans‐Peter Brunner‐La Rocca, Dong‐Ju Choi, Vijay Chopra, Eduardo Chuquiure‐Valenzuela, Nadia Giannetti, Juan Esteban Gómez‐Mesa, Stefan Janssens, James L. Januzzi, José Ramón González‐Juanatey, Béla Merkely, Stephen J. Nicholls, Sergio V. Perrone, Ileana L. Piña, Piotr Ponikowski, Michele Senni, Marie‐France Seronde, David Sim, Jindřich Špinar, Iain Squire, Stefano Taddei, Hiroyuki Tsutsui, Subodh Verma, Dragoş Vinereanu, Jian Zhang, Waheed Jamal, Sven Schnaidt, Janet Schnee, Martina Brueckmann, Stuart Pocock, Faı̈ez Zannad, Milton Packer - European Journal of Heart Failure 2020 cited by 136

  10. Evaluation of the Effects of Sodium–Glucose Co-Transporter 2 Inhibition with Empagliflozin on Morbidity and Mortality in Patients with Chronic Heart Failure and a Preserved Ejection Fraction: Rationale for and Design of the EMPEROR-Preserved Trial

    Authors: Stefan D. Anker, Javed Butler, Gerasimos Filippatos, Waheed Jamal, Afshin Salsali, Janet Schnee, Karen Kimura, Cordula Zeller, Jyothis T. George, Martina Brueckmann, Faı̈ez Zannad, Milton Packer - European Journal of Heart Failure 2019 cited by 251

  11. Regional and ethnic influences on the response to empagliflozin in patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial

    Authors: Carolyn S.P. Lam, João Pedro Ferreira, Egon Pfarr, David Sim, Hiroyuki Tsutsui, Stefan D. Anker, Javed Butler, Gerasimos Filippatos, Stuart Pocock, Naveed Sattar, Subodh Verma, Martina Brueckmann, Janet Schnee, Daniel Cotton, Faı̈ez Zannad, Milton Packer - European Heart Journal 2021 cited by 57

  12. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE‐MODEL randomized trial

    Authors: Bengt I. Eriksson, O.E. Dahl, Nadia Rosencher, Andreas Kurth, C. Niek van Dijk, Simon P. Frostick, Peter Kälebo, Anita Vedel Christiansen, Stefan Hantel, Rohan Hettiarachchi, Janet Schnee, Harry R. Büller - Journal of Thrombosis and Haemostasis 2007 cited by 984

  13. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II)

    Authors: Ola Dahl, Michael H. Huo, Andreas Kurth, Stefan Hantel, Karin Hermansson, Janet Schnee, Richard J. Friedman, Bengt I. Eriksson, for the RE-NOVATE II Study Group - Thrombosis and Haemostasis 2011 cited by 399

  14. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial

    Authors: Bengt I. Eriksson, Ola E. Dahl, Nadia Rosencher, Andreas Kurth, C. Niek van Dijk, Simon P. Frostick, Martin H. Prins, Rohan Hettiarachchi, Stefan Hantel, Janet Schnee, Harry R. Büller - The Lancet 2007 cited by 1,116

  15. Oral Thrombin Inhibitor Dabigatran Etexilate vs North American Enoxaparin Regimen for Prevention of Venous Thromboembolism After Knee Arthroplasty Surgery

    Authors: Jeffrey S Ginsberg, Jeffrey S. Ginsberg, Bruce L. Davidson, Philip C. Comp, Charles W. Francis, Richard J. Friedman, Michael H. Huo, Jay R. Lieberman, James E. Muntz, Gary E. Raskob, M L Clements, Stefan Hantel, Janet Schnee - The Journal of Arthroplasty 2008 cited by 631

  16. Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-Preserved

    Authors: Stefan D. Anker, Javed Butler, Muhammad Usman, Gerasimos Filippatos, João Pedro Ferreira, Edimar Alcides Bocchi, Michael Böhm, Hans‐Peter Brunner‐La Rocca, Dong‐Ju Choi, Vijay Chopra, Eduardo Chuquiure‐Valenzuela, Nadia Giannetti, Juan Esteban Gómez‐Mesa, Stefan Janssens, James L. Januzzi, José Ramón González‐Juanatey, Béla Merkely, Stephen J. Nicholls, Sergio V. Perrone, Ileana L. Piña, Piotr Ponikowski, Michele Senni, David Sim, Jindřich Špinar, Iain Squire, Stefano Taddei, Hiroyuki Tsutsui, Subodh Verma, Dragoş Vinereanu, Jian Zhang, Tomoko Iwata, Janet Schnee, Martina Brueckmann, Stuart Pocock, Faı̈ez Zannad - Nature Medicine 2022 cited by 37

  17. Comparison of Investigator-Reported and Centrally Adjudicated Heart Failure Outcomes in the EMPEROR-Reduced Trial

    Authors: Peter E. Carson, John R. Teerlink, Michel Komajda, Inder S. Anand, Stefan D. Anker, Javed Butler, Wolfram Doehner, João Pedro Ferreira, Gerasimos Filippatos, Markus Haass, Alan B. Miller, Steen Pehrson, Stuart Pocock, Sven Schnaidt, Janet Schnee, Faı̈ez Zannad, Milton Packer - JACC Heart Failure 2023 cited by 16

  18. Osteopontin modulates angiotensin II- induced fibrosis in the intact murine heart

    Authors: Alan R. Collins, Janet Schnee, Wei Wang, Sarah Kim, Michael C. Fishbein, Dennis Bruemmer, Ronald E. Law, Susanne B. Nicholas, Robert S. Ross, Willa A. Hsueh - Journal of the American College of Cardiology 2004 cited by 142

  19. Human homologs of the Xenopus oocyte cortical granule lectin XL35

    Authors: J K Lee, Janet Schnee, Mabel Pang, Margreet A. Wolfert, Linda G. Baum, Kelley W. Moremen, Marsha L. Pierce - Glycobiology 2001 cited by 110

  20. Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: A pooled analysis of three trials

    Authors: Richard J. Friedman, O.E. Dahl, Nadia Rosencher, Joseph A. Caprini, Andreas Kurth, C. W. Francis, Andreas Clemens, Stefan Hantel, Janet Schnee, Bengt I. Eriksson - Thrombosis Research 2010 cited by 141

  21. Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial

    Authors: Milton Packer, Stefan D. Anker, Javed Butler, Gerasimos Filippatos, João Pedro Ferreira, Stuart Pocock, Hans‐Peter Brunner‐La Rocca, Stefan Janssens, Hiroyuki Tsutsui, Jian Zhang, Martina Brueckmann, Waheed Jamal, Daniel Cotton, Tomoko Iwata, Janet Schnee, Faı̈ez Zannad - European Heart Journal 2020 cited by 136

  22. A comparison of the safety and effectiveness of dabigatran and warfarin in non-valvular atrial fibrillation patients in a large healthcare system

    Authors: Janet Schnee, Kathy Fraeman, Kimberly Siu, Matthew W. Reynolds, Jenna Collins, Eric Schwartzman, Todd C. Villines - Thrombosis and Haemostasis 2015 cited by 125

  23. A Randomized Trial of Dabigatran Versus Warfarin in the Treatment of Acute Venous Thromboembolism (RE-COVER II)

    Authors: Sam Schulman, Ajay K. Kakkar, Sebastian Schellong, Samuel Z. Goldhaber, Eriksson Henry, Patrick Mismetti, Anita Vedel Christiansen, Janet Schnee, Clive Kearon - Blood 2011 cited by 93

  24. Construction and expression of a recombinant antibody-targeted plasminogen activator.

    Authors: Janet Schnee, Marschall S. Runge, Gary R. Matsueda, N. W. Hudson, Jonathan G. Seidman, E Haber, Thomas Quertermous - National Academy of Sciences, Proceedings of the National Academy of Sciences 1987 cited by 91